Conferences / Events

  • No events scheduled. Please check back soon!

Brain Tumor News!

Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!
Displaying Stories 1 to 20 of 6,821
Next 20

11/23/20 New version of NCCN Guidelines for CNS Cancers        

 This is considered the standard of care for the treatment of brain tumors in the USA.  It doesn't include GammaTile since although approved and worthwhile are not available everywhere yet - hopefully they will be added to the next version!

    These guidelines say for Glioblastoma, that Clinical Trials should be considered first, then if not possible, they now include Optune and Temodar along with radiation and surgery as the recommended treatment.

11/22/20 INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo┬« (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting        

 This was one of the highlights of this week SNO conference.  The concept is elegant  read about it on the company's website. Impressive early results.

11/22/20 Brain tumor patients get to interview celebrities!        

 This was a lot of fun. Thanks to Novocure for setting it up!

11/22/20 CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy        

 This is preclinical work but fascinating new approach.  CRISPR is a gene editing tool which can be programmed to cut out any gene. This first attempt is proof of the principle that it can be directed to tumors inside a live animal.  The possibilities are endless, perhaps starting with other genes in the tumor like the MGMT gene which creates a repair enzyme which offers resistence to Temodar, or to genes in the entire body such as any of the oncogenes like the BRCA genes which increase chances of many types of cancer. 

11/22/20 DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting        

 This is another one of the highlights from the SNO conference this week.  Exciting results in recurrent Glioblastoma. Median overall survival of 12.5 months compared to historic controls of 7.2 months.  Another elegant solution - see their website for details!   When we get some of these treatments approved and can start combining them, we will see major breakthroughs!


 I went to the presentation on this and it was impressive. RNL is a nanoliposomal formulation that  delivered directly to where it is needed in the brain via convection enhanced delivery.  It releases radiation in a much higher dose to the tumor bed than external beam radiation does, and a smaller dose to the surrounding tissue.  It is still very early of course but the concept is elegant and early data looks good.  They reported that patients who previously used Avastin did not do as well as those who never used Avastin, but in the presentation it was explained that the convection enhanced delivery of the patients who used Avastin was difficult and only reached about 1/2 of the tumor coverage that those who never had Avastin achieved. Perhaps this is a technical problem that can be solved so it helps both groups.

11/19/20 NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)        

 This should allow for the more complete removal of these tumors!

11/19/20 Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting        

 This is an impressive volume of research and most of it is from external researchers not connected to the company that makes Optune.   I will view them all and report back on the highlights after the SNO meeting ends!

11/17/20 xCures launches xACCESS - A new module in their AI-assisted clinical platform        

 Through a collaboration with Cancer Commons and xCures, the Musella Foundation is proud to offer our patients free access to this system. View the press release and watch the video to see how the program works.  This module is what powers our "A Patient-Centric Platform Trial for Precision Oncology"  NCT03793088. 

This program will evaluate you and help find the best treatment options for your specific case. We then try to help you get access to them if needed. Then we follow up to see what treatments you do and the outcome so we learn from every patient.  To get started, go to and click on FIND TREATMENTS then on FULL SERVICE.

The Musella Foundation is focused on Brain Tumors, but Cancer Commons  also handles these tumor types: Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, and Hepatocellular Carcinoma. It also handles any type of cancer that has one of these specific mutations: MAPK, KRAS, BRAF, NRAS, HRAS, MEK and ERK. For details go to Cancer Commons.Org

Disclaimer: Al Musella owns stock in xCures.


11/17/20 OncoSynergy Opens Enrollment for Clinical Trial of New Cancer Antibody Therapy, OS2966, in Patients with Recurrent Glioblastoma        

When Avastin is used for a brain tumor, it starves the brain tumor. The tumor reacts by trying to escape and invades the surrounding tissue. Theoretically, this is driven by the tumor expressing Beta 1 integrins (CD29), which signals the cells to move and grow So this trial targets those Beta 1 integrins in the hope of allowing the Avastin to kill the tumor and this new treatment to stop the escape mechanism.  The Musella Foundation has awarded 2 grants to the scientists to help develop this. It makes a lot of sense. Let's hope it works!


 This is a webinar to announce the results of their clinical trial.  It is an exciting new type of treatment involving  nanoliposome-encapsulated radionuclides.  Will be keeping an eye on this.

11/15/20 Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study        

 Leptomeningeal spread is when the cancer spreads to the lining of the brain and/or spinal cord.   A big problem with it is that most clinical trials will exclude you if you have leptomeningeal spread, and there are no approved treatments that really help much. However, there is an exciting clinical trial about to open that uses Car-t cell therapy to try to treat leptomenigeal spread.  If you are interested in details, contact me. When the trial opens I will announce it in a news blast.

11/13/20 GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors        

 GammaTiles are FDA approved. They are implanted at the time of surgery and slowly release radiation to the tumor bed. They are not available everywhere yet but will be soon. Ask your surgeon about them. This press release describes the registry that will track patients who use GammaTiles. That is a fantastic idea and all new treatments should do this! 

11/12/20 Novocure: A Disruptive Growth Play In Cancer Treatments        

 This article is targeted to investors and I usually do not post such articles but it talks about something very important to us.  First they show the graph from the big randomized phase 3 trial of Optune for newly diagnosed Glioblastoma. This shows that the median overal survival for this new standard of care is 24.5 months.  This number should be used going forward when talking about the average survival for glioblastoma.  I have recently read articles that quote the survival as little as 14 months even though the Temodar trial showed it was 19 months before Optune..  

Next, they talk about combinations. I feel combinations are the key to the cure, and that is the basis of our organizations - we help patients find the best combinations and track the outcomes to home in on the cure.  They show some preliminary data on the combination of Optune with radiation. The traditional way to use Optune is wait a few weeks after radiation to give the skin a chance to heal before starting Optune.   This graph shows that in the lab, radiation and Optune are very synergistic.  Novocure is about to open a new randomized phase 3 trial testing what is the best time to start using Optune:  either at the start of radiation or a few weeks after radiation ends. They did a pilot study and saw it was technically possible and the side effects of skin irritation were manageable.

They also talk about combinations with Taxol and checkpoint inhibitors.  These are really exciting.  There should be a lot of new research reported at the upcoming Society of Neurooncology meeting! Stay tuned!

11/10/20 Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series        

 This shows that it is possible to use Optune even in kids as young as 4 years old.   This study was designed to show that it can be done. Now they have to try it at the right time to see how well it works.  They chose heavily pretreated kids who were out of options and used this as a last resort, which is not the best time to use it. I feel it should be used right at the start, when it had the best chance of helping - as the large newly diagnosed gbm study showed compared to the recurrent gbm study.

11/05/20 First Patient Treated With Experimental Therapy For Deadly Childhood Brain Cancer        

 This is an exciting clinical trial for DIPG. CAR-T cell therapy has made tremendous progress in other types of cancer such as lymphomas. Hopefully it will work for DIPG.  I wish this patient (and her team of doctors) the best of luck!

11/05/20 Oncoceutics Receives Foundation Grants to Establish an Expanded Access Program for ONC201        

 The Onc-201 expanded access program is open again.  We (the Musella Foundation) contributed $25,000 to help get this reopened, but we are no longer running the program. This is for people with DIPG or DMG with the H3K27M mutation!


 We are also announcing a new program to help patients find the best treatment options!

11/04/20 Problem With News Blast Yesterday        

Sorry about the problems yesterday - should be fixed now.  We are including the articles from yesterday again here - below!

Let us know if you still have problems or any ideas for future articles!

11/03/20 Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma        

 Amazing results seen.  To me, this is enough proof that the drug works, and it should be approved by the FDA so that we can find ways to make it work better.  There is no reason to withhold this from the kdis, young adults and rarely adults, with DMG and brainstem glioma who need it. There is no effective treatment approved. This has minimal side effects. Why wait?

Displaying Stories 1 to 20 of 6821
Next 20